Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
Annals of Oncology, 06/13/2012
Janjigian YY et al. – Approximately 20% of Western patients with metastatic gastric cancer are human epidermal growth factor receptor 2 (HER2) positive. Unlike breast cancer, HER2 positivity is not independently prognostic of patient outcome in metastatic gastric or gastroesophageal junction (GEJ).